Eric M. Dube - 31 Jan 2026 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Reporting relationship: CHIEF EXECUTIVE OFFICER, Director
Issuer ticker: TVTX
Reported as of: 31 Jan 2026
Net transaction value: -$3,230,316
SEC form: 4
Accepted by SEC: 03 Feb 2026, 21:30:16 UTC
Prior SEC filing: 27 Jan 2026
Next SEC filing: 24 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Elizabeth E. Reed, Attorney-in-Fact

Key filing fact

Eric M. Dube filed Form 4 for Travere Therapeutics, Inc. (TVTX) on 03 Feb 2026.

Key facts

This page summarizes Eric M. Dube's Form 4 filing for Travere Therapeutics, Inc. (TVTX).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Feb 2026, 21:30.

Change

Previous filing in this sequence was filed on 27 Jan 2026.
Current net transaction value: -$3,230,316.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001763494 Primary reporting owner

Dube Eric M

Relationship: CHIEF EXECUTIVE OFFICER, Director
Address: C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DR., SUITE 300, SAN DIEGO
Signature: /s/ Elizabeth E. Reed, Attorney-in-Fact
Signature date: 03 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TVTX transaction

Common Stock

Award

Transaction value: $0
Shares: +113,800
Change %: +27%
Price: $0.000000
Shares after: 532,973
Date: 31 Jan 2026
Ownership: Direct
Footnotes: F1

TVTX transaction

Common Stock

Sale

Transaction value: $2,130,451
Shares: -66,452
Change %: -12%
Price: $32.06
Shares after: 466,521
Date: 03 Feb 2026
Ownership: Direct
Footnotes: F2, F3

TVTX transaction

Common Stock

Sale

Transaction value: $1,099,864
Shares: -33,635
Change %: -7.2%
Price: $32.70
Shares after: 432,886
Date: 03 Feb 2026
Ownership: Direct
Footnotes: F2, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TVTX transaction Derivative

Employee stock option (right to buy)

Award

Transaction value: $0
Shares: +303,600
Change %
Price: $0.000000
Shares after: 303,600
Date: 31 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 303,600
Exercise price: $33.10
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

Footnote F2

This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

Footnote F3

The weighted average sale price for the transaction reported was $32.06, and the range of prices were between $31.52 and $32.52. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Footnote F4

The weighted average sale price for the transaction reported was $32.70, and the range of prices were between $32.5248 and $32.88. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Footnote F5

One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.